↓ Skip to main content

American Association for Cancer Research

Article Metrics

Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Overview of attention for article published in Blood Cancer Discovery, September 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#13 of 100)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
5 news outlets
twitter
19 tweeters

Citations

dimensions_citation
1 Dimensions